OpenAlex
P48.16 The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis
Work
Year: 2021
Type: article
Cites:
Cited by:
Related to: 10
FWCI:
Citation percentile (by year/subfield):
Subfield: Oncology
Field: Medicine
Sustainable Development Goal Good health and well-being
Open Access status: bronze